Hidenori Ibata

Tsu, 5141101, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Real-World Comparative Study of Atezolizumab-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer.

Real-World Comparative Study of Atezolizumab-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer.

Journal: Cancers
Published: October 08, 2025

First Report of RET Fusion-Positive Lung Adenocarcinoma With Miliary Intrapulmonary Metastases Responsive to Selpercatinib: A Case Report.

First Report of RET Fusion-Positive Lung Adenocarcinoma With Miliary Intrapulmonary Metastases Responsive to Selpercatinib: A Case Report.

Journal: Clinical case reports
Published: March 14, 2025

Transforming Lung Cancer Management: A Promising Case Study of Immune Checkpoint Inhibitor Success Following a Multidisciplinary Approach.

Transforming Lung Cancer Management: A Promising Case Study of Immune Checkpoint Inhibitor Success Following a Multidisciplinary Approach.

Journal: Diagnostics (Basel, Switzerland)
Published: August 30, 2024

Impact of immune-related adverse events on survival outcomes in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors.

Impact of immune-related adverse events on survival outcomes in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors.

Journal: Cancer medicine
Published: November 02, 2023

Blood DNA virome associates with autoimmune diseases and COVID-19.

Blood DNA virome associates with autoimmune diseases and COVID-19.

Journal: Nature genetics
Published: October 24, 2023

Impact of antimicrobial stewardship program-driven educational intervention for vancomycin loading dose on mortality.

Impact of antimicrobial stewardship program-driven educational intervention for vancomycin loading dose on mortality.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
Published: April 07, 2023

Next-generation sequencing clarified why first-line treatment with osimertinib was ineffective in an autopsied case of EGFR-mutated lung squamous cell carcinoma.

Next-generation sequencing clarified why first-line treatment with osimertinib was ineffective in an autopsied case of EGFR-mutated lung squamous cell carcinoma.

Journal: Thoracic cancer
Published: December 10, 2022

Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy.

Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy.

Journal: Cancers
Published: July 23, 2022

Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?

Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?

Journal: Cancers
Published: April 27, 2022

Complete withdrawal of glucocorticoids after dupilumab therapy in allergic bronchopulmonary aspergillosis: A case report.

Complete withdrawal of glucocorticoids after dupilumab therapy in allergic bronchopulmonary aspergillosis: A case report.

Journal: World journal of clinical cases
Published: April 25, 2021

Second-line therapy with first- or second-generation tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer patients with T790M-negative or unidentified mutation.

Second-line therapy with first- or second-generation tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer patients with T790M-negative or unidentified mutation.

Journal: Thoracic cancer
Published: January 02, 2021

Genetic determinants of risk in autoimmune pulmonary alveolar proteinosis.

Genetic determinants of risk in autoimmune pulmonary alveolar proteinosis.

Journal: Nature communications
Published: April 08, 2020
Showing 1-12 of 15

Last Updated: 09/26/2026